High concentrations of active plasminogen activator inhibitor-1 in porcine coronary artery thrombi

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 16, Issue 10, 1996, Pages 1277-1284

  Fay, William P ^a,b,c   Murphy, Joseph G ^b   Owen, Whyte G ^b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b MAYO CLINIC   (United States)

^c UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

myocardial infarction; platelets; thrombolysis; thrombosis

Indexed keywords

IODINE 125; PLASMINOGEN ACTIVATOR INHIBITOR 1; UROKINASE;

ACUTE HEART INFARCTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD CLOT LYSIS; CORONARY ARTERY THROMBOSIS; ENZYME INHIBITION; IMMUNOBLOTTING; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; SWINE; THROMBOCYTE AGGREGATION;

EID: 0029797070     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.16.10.1277     Document Type: Article

References (48)

1. Loskutoff DJ, Sawdey M, Mimuro J. Type 1 plasminogen activator inhibitor. Prog Hemost Thromb. 1989;9:87-115.
2. Schleef RR, Higgins DL, Pillemer E, Levitt LJ. Bleeding diathesis due to decreased functional activity of type 1 plasminogen activator inhibitor. J Clin Invest. 1989;83:1747-1752.
3. Fay WP, Shapiro AD, Shih JL, Schleef RR, Ginsburg D. Brief report: complete deficiency of plasminogen-activator inhibitor type 1 due to a frame-shift mutation. N Engl J Med. 1992;327:1729-1733.
4. Hamsten A, Wiman B, de Faire U, Blomback M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med. 1985;313:1557-1563.
5. Hamsten A, de Faire U, Walldius G, Dahlen G, Szamosi A, Landou C, Blomback M, Wiman B. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet. 1987;2:3-9.
6. Muller JE, Stone PH, Turi ZG, Rutherford JD, Czeisler CA, Parker C, Poole WK, Passamani E, Roberts R, Robertson T, et al. Circadian variation in the frequency of onset of acute myocardial infarction. N Engl J Med. 1985;313:1315-1322.
7. Angleton P, Chandler WL, Schmer G. Diurnal variation of tissue-type plasminogen activator and its rapid inhibitor (PAI-1). Circulation. 1989;79:101-106.
8. Sprengers ED, Akkerman JW, Jansen BG. Blood platelet plasminogen activator inhibitor: two different pools of endothelial cell type plasminogen activator inhibitor in human blood. Thromb Haemost. 1986;55:325-329.
9. Reilly CF, McFall RC. Platelet-derived growth factor and transforming growth factor-beta regulate plasminogen activator inhibitor-1 synthesis in vascular smooth muscle cells. J Biol Chem. 1991;266:9419-9427.
10. Fujii S, Sobel BE. Induction of plasminogen activator inhibitor by products released from platelets. Circulation. 1990;82:1485-1493.
11. Lamas GA, Flaker GC, Mitchell G, Smith SC Jr. Gersh BJ, Wun CC, Moye L, Rouleau JL, Rutherford JD, Pfeffer MA, et al. Effect of infarct artery patency on prognosis after acute myocardial infarction: the Survival and Ventricular Enlargement Investigators. Circulation. 1995;92:1101-1109.
12. Simes RJ, Topol EJ, Holmes DR Jr, White HD, Rutsch WR, Vahanian A, Simoons ML, Morris D, Betriu A, Califf RM, et al. Link between the angiographie substudy and mortality outcomes in a large randomized trial of myocardial reperfusion: importance of early and complete infarct artery reperfusion. GUSTO-I Investigators. Circulation. 1995;91:1923-1928.
13. Jang I, Gold H, Ziskind A, Fallon J, Holt R, Leinbach RD, May JD, Collen DD. Differential sensitivity of erythrocyte-rich and plateletrich arterial thrombi to lysis with recombinant tissue-type plasminogen activator. Circulation. 1989;79:920-928.
14. Levi M, Biemond BJ, van Zonneveld AJ, Wouter Ten Gate J, Pannekoek H. Inhibition of plasminogen activator inhibitor-1 activity results in promotion of endogenous thrombolysis and inhibition of thrombus extension in models of experimental thrombosis. Circulation. 1992;85:305-312.
15. Braaten JV, Handt S, Jerome WG, Kirkpatrick J, Lewis JC, Hantgan RR. Regulation of fibrinolysis by platelet-released plasminogen activator inhibitor 1: light scattering and ultrastructural examination of lysis of a model platelet-fibrin thrombosis. Blood. 1993;81:1290-1299.
16. Fay WP, Eitzman DT, Shapiro AD, Madison EL, Ginsburg D. Platelets inhibit fibrinolysis in vitro by both plasminogen activator inhibitor-1 dependent and independent mechanisms. Blood. 1994;83:351-356.
17. Handt S. Jerome WG, Braaten JV, Lewis JC, Kirkpatrick CJ. Hantgan RR. PAI-1 released from cultured human endothelial cells delays fibrinolysis and is incorporated into the developing fibrin clot. Fibrinolysis. 1994;8:104-112.
18. Marsh JJ, Konopka RG, Lang IM, Wang HY, Pedersen C, Chiles P, Reilly CF, Moser KM. Suppression of thrombolysis in a canine model of pulmonary embolism. Circulation. 1994;90:3091-3097.
19. Fay WP, Owen WG. Platelet plasminogen activator inhibitor: purification and characterization of interaction with plasminogen activators and activated protein C. Biochemistry. 1989;28:5773-5774.
20. Sherman PM, Lawrence DA, Yang AY, Vandenberg ET, Paielli D, Olson ST, Shore JD. Ginsburg D. Saturation mutagenesis of the plasminogen activator inhibitor-1 reactive center. J Biol Chem. 1992;267:7588-7595.
21. Murphy JG, Schwartz RS, Edwards WD, Camrud AR, Vlietstra RE, Holmes DR Jr. Percutaneous polymeric stents in porcine coronary arteries: initia! experience with polyethylene terephthalate stents. Circulation. 1992;86:1596-1604.
22. Schleef RR, Sinha M, Loskutoff DJ. Immunoradiometric assay to measure the binding of a specific inhibitor to tissue-type plasminogen activator. J Lab Clin Med. 1985;106:408-415.
23. Kvassman J, Shore JD. Purification of human plasminogen activator inhibitor (PAI-1) from Escherichia coli and separation of its active and latent forms by hydrophobic interaction chromatography. Fibrinolysis. 1995;9:215-221.
24. Wagner OF, de Vries C, Hohmann C, Veerman H, Pannekoek H. Interaction between plasminogen activator inhibitor type I (PAI-1) bound to fibrin and either tissue-type plasminogen activator (t-PA) or urokinase-type plasminogen activator (u-PA). J Clin Invest. 1989;84:647-655.
25. Reilly CF. Hutzelmann JE. Plasminogen activator inhibitor-1 binds to fibrin and inhibits tissue-type plasminogen activator-mediated fibrin dissolution. J Biol Chem. 1992;267:17128-17135.
26. Preissner KT, Holzhuter S, Justus C, Muller-Berghaus G. Identification of and partial characterization of platelet vitronectin: evidence for complex formation with platelet-derived plasminogen activator inhibitor-1. Blood. 1989;74:1989-1996.
27. Friedman M, Van den Bovenkamp GJ. The pathogenesis of a coronary thrombus. Am J Pathol. 1966;48:19-44.
28. Hekman CM, Loskutoff DJ. Endothelial cells produce a latent inhibitor of plasminogen activators that can be activated by denaturants. J Biol Chem. 1985;260:11581-11587.
29. Reilly CF, Fujita T, Mayer EJ, Siegfried ME. Both circulating and clot-bound plasminogen activator inhibitor-1 inhibit endogenous fibrinolysis in the rat. Arterioscler Thromb. 1991;11:1276-1286.
30. 2+ concentration. Biochemistry. 1995;34:9277-9281.
31. Carty DJ, Spielberg F, Gear ARL. Thrombin causes subsecond changes in protein phosphorylation of platelets. Blood. 1986;67:1738-1743.
32. Merlini PA, Bauer KA, Oltrona L, Ardissino D, Spinola A, Cattaneo M, Broccolino M, Mannucci PM, Rosenberg RD. Thrombin generation and activity during thrombolysis and concomitant heparin therapy in patients with acute myocardial infarction. J Am Coll Cardiol. 1995;25:203-209.
33. Parise P, Hauert J, lorio A, Callegari P, Agnelli G. Streptokinase and rt-PA activate platelets by a different way: implications on the rethrombosis rate after their administration in myocardial infarction. J Lab Clin Med. 1995;125:212-221.
34. Schafer AI, Maas AK, Ware JA, Johnson PC, Rittenhouse SE, Salzman EW. Platelet protein phosphorylation, elevation of cytosolic calcium, and inositol phospholipid breakdown in platelet activation induced by plasmin. J Clin Invest. 1986;78:73-79.
35. Jorgensen L, Rowsell HC, Hovig T, Mustard JF. Resolution and organization of platelet-rich mural thrombi in carotid arteries of swine. Am J Pathol. 1967;51:681-719.
36. Potter van Loon BJ, Rijken DC, Brommer EJP, Van der Maas APC. The amount of plasminogen, tissue-type plasminogen activator and plasminogen activator inhibitor type 1 in human thrombi and the relation to ex-vivo lysibility. Thromb Haemost. 1992;67:101-105.
37. Robbie LA, Bennett B, Croll AM, Brown PAJ, Booth NA. Proteins of the fibrinolytic system in human thrombi. Thromb Haemost. 1996;75:127-133.
38. Biemond BJ, Levi M, Coronet R, Janse MJ. ten Gate JW, Pannekoek H. Thrombolysis and reocclusion in experimental jugular vein and coronary artery thrombosis: effects of a plasminogen activator inhibitor type 1-neutralizing monoclonal antibody. Circulation. 1995;91:1175-1181.
39. Booth NA, Simpson AJ, Croll A, Bennett B, MacGregor IR. Plasminogen activator inhibitor (PAI-1) in plasma and platelets. Br J Haematol. 1988;70:327-333.
40. Lang IM, Marsh JJ, Moser KM, Schleef RR. Presence of active and latent type 1 plasminogen activator inhibitor associated with porcine platelets. Blood. 1992;80:2269-2274.
41. Deguchi K, Murashima S, Nishikawa M, Shirakawa S. Study on fibrinolysis and platelet function. Nippon Rinsho. 1992;50:297-302.
42. Wilbourn B, Harrison P, Lawrie A, Savariau E, Savidge G, Cramer EM. Porcine platelets contain an increased quantity of ultra-high molecular weight von Willebrand factor and numerous alpha-granular tubular structures. Br J Haemaiol 1993;83:608-615.
43. Mizuno K, Satomura K, Miyamoto A, Arakawa K, Shibuya T, Arai T, Kurita A, Nakamura H, Ambrose JA. Angioscopic evaluation of coronary-artery thrombi in acute coronary syndromes. N Engl J Med. 1992;326:287-291.
44. Collen D, Bounameaux H, De Cock F, Lijnen HR, Verstraete M. Analysis of coagulation and fibrinolysis during intravenous infusion of recombinant human tissue-type plasminogen activator in patients with acute myocardial infarction. Circulation. 1986;73:511-517.
45. Warnes CA, Roberts WC. Sudden coronary death: comparison of patients with to those without coronary thrombus at necropsy. Am J Cardiol. 1984;54:1206-1211.
46. Madison EL, Goldsmith EJ, Gerard RD, Gething MH, Sambrook JF. Serpin-resistant mutants of human tissue-type plasminogen activator. Nature. 1989;339:721-724.
47. Keyt BA, Paoni NF, Refino CJ, Berleau L, Nguyen H, Chow A, Lai J, Pena L, Pater C, Ogez J, et al. A faster-acting and more potent form of tissue plasminogen activator. Proc Natl Acad Sci U S A. 1994;91:3670-3674.
48. Benedict CR, Refino CJ, Keyt BA, Pakala R, Paoni NF, Thomas GR, Bennett WF. New variant of human tissue plasminogen activator (TPA) with enhanced efficacy and lower incidence of bleeding compared with recombinant human TPA. Circulation. 1995;92:3032-3040.